Sign in Subscribe
Trump, Donald

Trump's 30-80% Cut in Drug Prices Throws Indian Pharma Exports into Uncertainty

Strategic Insights

— 1 min read

India's $30 billion pharma exports to the US, accounting for over a third of its annual exports, are poised to be severely impacted by US President Donald Trump's decision to cut the prices of prescription drugs by 30-80%. The move is likely to make shipments unviable for many Indian exporters, particularly in the generic segment, as prices are already depressed in the US. The Nifty Pharma index took a hit, underperforming the benchmark Nifty by a significant margin, as stocks like Sun Pharma and Glenmark fell on market fears of unviable pricing and potential exits from key US product categories.

Key Takeaways:

  • Indian pharma exports of over $30 billion annually, with more than a third going to the US, may be severely impacted by the price cut.
  • The US pharma market of $96 trillion, with a staggering 40% share of Indian drugs in volume terms, is likely to experience exits of Indian companies from specific product categories.
  • Shashank Krishnakumar, senior research analyst at Emkay Global Financial Services, noted that a 50% or more price cut would hurt the US formulations market, particularly due to the immediate potential impact on branded products.
  • Shrikant Akolkar, an analyst at Nuvama Institutional Equities, stated that Indian branded players like Sun Pharma, Biocon, and Zydus Life may see an impact upon strict implementation.
  • The Nifty Pharma index has declined 9.86% on a year-to-date basis, underperforming the Nifty, which has gained 5.41%.
  • The US pharma market is 90% branded generics and 10% innovative/patented products, making the generic segment more vulnerable to price cuts.

Statistics:

  • US President Donald Trump's executive order faces opposition from pharma companies, which operate on thin margins of 5-10%.
  • The Trump order aims to cut prescription drug prices by 30-80% in the US.
  • The US pharma market is valued at $96 trillion, with a staggering 40% share of Indian drugs in volume terms.
  • Indian pharma exports to the US account for over a third of the country's annual exports, valued at over $30 billion.
  • The Nifty Pharma index has declined 9.86% on a year-to-date basis (as of 2025).
  • The top losers in the Nifty Pharma index included Sun Pharma (down 3.15%), Ajanta Pharma (down 2.28%), and Glenmark Pharma (down 1.44%).

Sources:

  • US President Donald Trump's social media post
  • Reuters
  • Emkay Global Financial Services
  • Nuvama Institutional Equities
  • Financial Express (FE)

Read more